Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orbus Medical Technologies Inc.

Division of OrbusNeich

Latest From Orbus Medical Technologies Inc.

Research In Brief

Exact Sciences’ and Genomic Health announce favorable results for colon cancer tests. Boston Scientific launches trial of MRI-safe pacemaker. More research news.

Medical Device

X-Cell Medical Inc.

X-Cell Medical's mission is to discover and develop alternative drugs for device-drug combinations, believing that the drug in such combination products is the most valuable component. The company has in-house expertise in drug discovery, formulation, and polymer coatings, as well as a deep set of cardiovascular device experience, coming from its medical advisory board, which consists of some of the most influential cardiology device users in the world.
BioPharmaceutical Medical Device

After Drug-Eluting Stents: Making the Heart Smaller and the Market Larger

According to a recent report by Windhover/Medtech Insight, "Emerging US Markets for Myocardial Revascularization, Repair, and Regeneration Products and Technologies," drug-eluting stents achieved sales of $1.2 billion in 2003, and sales are expected to continue to grow at a compound annual rate of 27.5% to $4.1 billion in 2008. But revascularization technologies are only one category that offer grwoth opportunities for medtech companies. Another group of players hopes to address patients trending towards heart failure, as a result of heart scar formation or the death of heart muscle cells following a heart attack. New devices and device-enabled products have the potential to intervene in both of these structural processes in ways that existing heart failure drugs, which are merely palliative, can't. Medtech estimates that two strategies-cell therapies for heart muscle regeneration and remodeling devices for the heart--will serve a market that could grow to almost $190 million by 2008.
BioPharmaceutical Medical Device

PCR's Pas de Deux

As it has for each of the past several years, much of the discussion at this year's Paris Course on Revascularization (PCR) centered on drug-eluting stents. From the latest results of the Taxus and Endeavor clinical trials to reports of the marketplace battle between Cypher and Taxus, drug-eluting stents are dominated by large companies. But we're only at the beginning of drug-eluting stents' technology race, and small companies, with innovative approaches to everything from delivery systems to fundamental biology, will increasingly make their voices heard as new technology comes out of the lab. And they're likely to use collaborations with others, particularly other start-ups, as a means of getting to market faster.
Strategy Clinical Trials
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • OrbusNeich
  • Senior Management
  • David Camp, Pres. & CEO
  • Contact Info
  • Orbus Medical Technologies Inc.
    Phone: (954) 730-0711
    5363 NW 35th Ave.
    Fort Lauderdale, FL 33309